Compare Mesoblast Limited (MESO) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs AT&T Inc. — how do they compare? Mesoblast Limited trades at $16.38 (market cap $2.17B), while AT&T Inc. trades at $22.3 (market cap $152.52B). The key difference: AT&T Inc. is far larger — about 70.3× Mesoblast Limited's market cap, and AT&T Inc. pays a 5.06% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | T | |
|---|---|---|
Market Cap | $2.17B | $152.52B |
Sector | Technology | Media |
52-Week High | $20.96 | $29.62 |
52-Week Low | $12.88 | $20.49 |
Enterprise Value | $2.17B | $297.87B |
Dividend Yield | — | 5.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
AT&T (T) trades at $22.26, up 2.13% with a bullish technical signal despite mixed moving averages. The stock shows strong fundamentals with a low P/E of 7.39, robust profitability margins (net margin 16.94%), and consistent earnings beats in recent quarters. Recent cash flow improvement to $15.12B in 2025 and declining debt-to-asset ratio to 32.59% in 2024 signal financial health. The company faces competitive pressures in telecom but benefits from fiber expansion and stable wireless pricing.
Outlook remains positive with analyst consensus target of $25.61 offering 15% upside. Key opportunities include dividend yield support and fiber growth, while risks involve intense telecom competition and potential earnings volatility. Wall Street sentiment is cautiously optimistic with 41% buy ratings, though technical indicators show some overbought conditions near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
